Loading Events

« All Events

  • This event has passed.

Mydecine Speaker Series – Psychedelic Solutions [ONLINE]

December 15, 2020 @ 9:00 am - 10:30 am

by Microdose Psychedelic Insights
Join us to find out how cutting edge research is igniting mainstream medical interest to unlock the potential of psychedelic therapies.

About this Event

Microdose invites you to join Mydecine Speaker Series dedicated to exploration of the incredible findings around the current psychedelic research and what the path to mainstream acceptance looks like.

Mydecine Speaker Series – Psychedelic Solutions:

Dec. 15th 2020. 12:00-1:30pm EST

The first in the Mydecine Speaker Series – Psychedelic Solutions will explore how cutting edge research is igniting medical interest in addressing the mental health crisis.

Panelists will be asked to reflect on the past, present, and future potential of the psychedelic space in relation to the mental health crisis.

Can’t make the live show? Don’t worry, we provide access to recordings for every ticket holder.

Panel Agenda & Format:

Dec 15th: 12:00-13:30 EST

  • Event Overview and Panelist Introductions: 10 Minutes
  • Organic Panel Conversation: 60 minutes
  • Live Audience Q&A’s: 20 minutes


The first in the Mydecine Speaker Series – Psychedelic Solutions will explore how cutting edge research is igniting medical interest in addressing the mental health crisis.

Robert Roscow, MA, Mydecine, Chief Scientific Officer & Co-Founder

Robert Roscow, MA (Chief Scientific Officer & Co-Founder). Mr. Roscow is a highly educated geneticist with impressive knowledge around multiple arts of science. He has spent his academic and professional careers looking for valuable and unique active medicinal compounds found in nature. The last two companies Mr. Roscow applied his innovations to were Canopy Growth and ebbu where he was the head of their genetics divisions.‍

Mr. Roscow has already leveraged an expertise in genomics, evolution, and molecular biology to maximize the industrial production of cannabinoids and their use in a pharmacological context. His work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his focus on the vast healing potential of the safe and effective compounds found in fungi.

Robin Carhart-Harris, Ph.D, Mydecine Scientific Advisory Board Member

Dr Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, Robin has designed and completed human brain imaging studies with LSD, psilocybin, MDMA and DMT, a clinical trial of psilocybin for treatment-resistant depression, a double-blind randomised controlled trial comparing psilocybin with escitalopram for major depressive disorder and a multimodal imaging study in healthy volunteers receiving psilocybin for the first time. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world.

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC (Chief Medical Officer, Mydecine Innovations Group)

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC serves as Chief Medical Officer for Mydecine Innovations Group. Dr. Jetly brings to Mydecine a wealth of experience not only as a medical advocate for the use of psychedelic-assisted psychotherapy, but also as a prominent voice in the fight against post-traumatic stress disorder (PTSD) and other mental health issues facing vulnerable populations like veterans and first responders. Dr. Jetly currently serves as Academic Chair of Military Mental Health at The Royal’s Institute of Mental Health Research, and as an associate professor of psychiatry at Dalhousie University (Halifax), and the University of Ottawa. In 2015, he was appointed, “The Canadian Forces Brigadier Jonathan C. Meakins, CBE, RCAMC Chair in Military Mental Health.” He has published numerous articles in professional journals and presents nationally and internationally on such topics as PTSD and operational psychiatry.

“Over the years as a general duty medical officer and then a uniformed psychiatrist I have become acutely aware of the importance and challenge of transition from active duty to veteran,” said Dr. Jetly. “I am now facing the same process and am thankful that my transition will allow me to continue to work in the space that confronts the challenge of PTSD. Having deployed in missions in Rwanda and the Middle East, and witnessing first hand intense trauma of combat during deployments in Afghanistan, I am keenly aware of the suffering of the incredible men and women that sacrifice so much in our Armed Forces and suffer from operational stress injuries.”

As Chief Medical Officer, Dr. Jetly will lead Mydecine’s clinical trials related to psychedelic-assisted psychotherapy using psilocybin to treat PTSD. Dr. Jetly will also keep Mydecine abreast of new scientific research related to psychedelics, and offer strategic guidance as it relates to all aspects of patient care, medical safety, medical compliance and the administration of psychedelics. Additionally, Dr. Jetly will also engage medical professionals and veterans’ organizations through outreach and educational offerings regarding the use of psychedelics as medicine.

Ruth Lanius, MD, PhD, is Professor of Psychiatry and the director of the posttraumatic stress disorder (PTSD) research unit at the University of Western Ontario

Ruth Lanius, MD, PhD, is Professor of Psychiatry and the director of the posttraumatic stress disorder (PTSD) research unit at the University of Western Ontario.

She established the Traumatic Stress Service and the Traumatic Stress Service Workplace Program, both services that specialize in the treatment and research of Posttraumatic Stress Disorder (PTSD) and related comorbid disorders.

Ruth currently holds the Harris-Woodman Chair in Mind-Body Medicine at the Schulich School of Medicine & Dentistry at the University of Western Ontario. Her research interests focus on studying the neurobiology of PTSD and treatment outcome research examining various pharmacological and psychotherapeutic methods.

Ruth has authored more than 100 published papers and chapters in the field of traumatic stress and is currently funded by several federal funding agencies. She regularly lectures on the topic of PTSD nationally and internationally. She has recently published a book Healing the traumatized self: consciousness, neuroscience, treatment with Paul Frewen which we talk about in the interview.

Yeji Lee, Journalist, Business Insider

Yeji Jesse Lee is a journalist at Business Insider where she focuses on the cannabis and psychedelics industries.

At BI, Yeji has covered the burgeoning psychedelics space as it’s garnered more interest from traditional biotech investors and Canadian banks alike over the past year. She’s profiled top executives from companies like Compass and ATAI and has written about emerging trends in the industry as some companies have geared up to go public and others have laid out the groundwork to gain FDA approval on psychedelics-based treatments.

Yeji joined Business Insider after graduating from Columbia University’s School of Journalism. She was raised between South Korea and Canada and is now based in New York.


December 15, 2020
9:00 am - 10:30 am
Event Category:
Event Tags:




Microdose Psychedelic Insights